De Mulder PH - Search Results

1

Consensus regarding multiple day and rescue antiemetic therapy.

De Mulder PH, Roila F, Kris MG, Marty MM. De Mulder PH, et al. Support Care Cancer. 1998 May;6(3):248-52. doi: 10.1007/s005200050162. Support Care Cancer. 1998. PMID: 9629878 Review.

2

Delayed emesis following anticancer chemotherapy.

Kris MG, Roila F, De Mulder PH, Marty M. Kris MG, et al. Among authors: de mulder ph. Support Care Cancer. 1998 May;6(3):228-32. doi: 10.1007/s005200050158. Support Care Cancer. 1998. PMID: 9629874 Review.

3

Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study.

Punt CJ, Burghouts JT, Croles JJ, van Liessum PA, de Mulder PH, Kamm Y. Punt CJ, et al. Among authors: de mulder ph. Cancer. 1993 Oct 1;72(7):2107-11. doi: 10.1002/1097-0142(19931001)72:7<2107::aid-cncr2820720708>3.0.co;2-m. Cancer. 1993. PMID: 8374869 Clinical Trial.

4

Osteonecrosis in patients with testicular tumours treated with chemotherapy.

van den Berkmortel F, de Wit R, de Rooy J, DeMulder P. van den Berkmortel F, et al. Neth J Med. 2004 Jan;62(1):23-7. Neth J Med. 2004. PMID: 15061230 Free article.

5

Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication.

Kruit WH, Punt KJ, Goey SH, de Mulder PH, van Hoogenhuyze DC, Henzen-Logmans SC, Stoter G. Kruit WH, et al. Among authors: de mulder ph. Cancer. 1994 Nov 15;74(10):2850-6. doi: 10.1002/1097-0142(19941115)74:10<2850::aid-cncr2820741018>3.0.co;2-t. Cancer. 1994. PMID: 7954247

6

Renal cancer.

Corgna E, Betti M, Gatta G, Roila F, De Mulder PH. Corgna E, et al. Among authors: de mulder ph. Crit Rev Oncol Hematol. 2007 Dec;64(3):247-62. doi: 10.1016/j.critrevonc.2007.04.007. Epub 2007 Jul 26. Crit Rev Oncol Hematol. 2007. PMID: 17662611 Review.

7

Hypothyroidism and goiter in a patient during treatment with interleukin-2.

Mattijssen VJ, De Mulder PH, Van Liessum PA, Corstens FH, Franks CR, Wagener DJ. Mattijssen VJ, et al. Among authors: de mulder ph. Cancer. 1990 Jun 15;65(12):2686-8. doi: 10.1002/1097-0142(19900615)65:12<2686::aid-cncr2820651215>3.0.co;2-d. Cancer. 1990. PMID: 2340468

8

Experience with dose and schedule variations in germ cell tumors.

De Mulder PH, de Wit R. De Mulder PH, et al. Among authors: de wit r. Anticancer Drugs. 1995 Oct;6 Suppl 5:43-52. doi: 10.1097/00001813-199510005-00005. Anticancer Drugs. 1995. PMID: 8845494 Review.

9

The 5-HT3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy.

Seynaeve C, de Mulder PH, Lane-Allman E, van Liessum PA, Verweij J. Seynaeve C, et al. Among authors: de mulder ph. Clin Oncol (R Coll Radiol). 1991 Jul;3(4):199-203. doi: 10.1016/s0936-6555(05)80739-3. Clin Oncol (R Coll Radiol). 1991. PMID: 1834161 Clinical Trial.

10

Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.

De Mulder PH, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Allman EL, Beranek P, Verweij J. De Mulder PH, et al. Ann Intern Med. 1990 Dec 1;113(11):834-40. doi: 10.7326/0003-4819-113-11-834. Ann Intern Med. 1990. PMID: 2146911 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

211 results

Search Page

Filters